Shukra Pharmaceuticals Ltd () News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 505931,
    "name": "Shukra Pharma.",
    "stock_name": "Shukra Pharma.",
    "full_name": "Shukra Pharmaceuticals Ltd",
    "name_url": "stocks-analysis/shukra-pharma",
    "exchange": 0,
    "exchangecode": "",
    "primexch": 0,
    "country_id": 34,
    "currency": "INR",
    "cmp": "33.34",
    "chg": -0.5,
    "chgp": "-1.48%",
    "dir": -1,
    "prev_price": "33.84",
    "mcapval": "1,459.89 Cr",
    "mcap": "Micro Cap",
    "scripcode": 524632,
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "India SENSEX",
    "isin": "INE551C01044",
    "curr_date": "Apr 13",
    "curr_time": "",
    "bse_nse_vol": "3.32 lacs",
    "exc_status": "Active",
    "traded_date": "Apr 13, 2026",
    "traded_date_str": "2026 04 13",
    "score": "",
    "scoreText": "",
    "Live": 1,
    "market_time": 1,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/shukra-pharma-505931-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Shukra Pharmaceuticals Ltd is Rated Hold",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/shukra-pharmaceuticals-ltd-is-rated-hold-3942495",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/4/ShukraPharmaceu_mojoScore_3942495.png",
        "date": "2026-04-11 10:10:02",
        "description": "Shukra Pharmaceuticals Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 17 Jul 2025. However, the analysis and financial metrics discussed here reflect the company’s current position as of 11 April 2026, providing investors with an up-to-date view of its fundamentals, returns, and market standing."
      },
      {
        "title": "Shukra Pharmaceuticals Ltd Technical Momentum Shifts Amid Mixed Indicator Signals",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/shukra-pharmaceuticals-ltd-technical-momentum-shifts-amid-mixed-indicator-signals-3935346",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/4/ShukraPharmaceu_technicaldot_3935346.png",
        "date": "2026-04-07 08:02:23",
        "description": "Shukra Pharmaceuticals Ltd has experienced a notable shift in price momentum, reflected in a complex interplay of technical indicators that suggest a transition from a mildly bullish trend to a sideways movement. Despite a strong one-week return outperforming the Sensex, the stock’s medium-term outlook remains cautious amid mixed signals from MACD, RSI, and moving averages."
      },
      {
        "title": "Shukra Pharmaceuticals Ltd is Rated Hold",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/shukra-pharmaceuticals-ltd-is-rated-hold-3927414",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/ShukraPharmaceu_mojoScore_3927414.png",
        "date": "2026-03-31 10:10:02",
        "description": "Shukra Pharmaceuticals Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 17 July 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 31 March 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook."
      },
      {
        "title": "Shukra Pharmaceuticals Ltd is Rated Hold",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/shukra-pharmaceuticals-ltd-is-rated-hold-3902930",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/ShukraPharmaceu_mojoScore_3902930.png",
        "date": "2026-03-20 10:10:03",
        "description": "Shukra Pharmaceuticals Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 17 July 2025. However, the analysis and financial metrics discussed below reflect the stock's current position as of 20 March 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing."
      },
      {
        "title": "Shukra Pharmaceuticals Ltd is Rated Hold",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/shukra-pharmaceuticals-ltd-is-rated-hold-3879248",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/ShukraPharmaceu_mojoScore_3879248.png",
        "date": "2026-03-09 10:10:02",
        "description": "Shukra Pharmaceuticals Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 17 Jul 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 09 March 2026, providing investors with an up-to-date perspective on the company’s performance and outlook."
      },
      {
        "title": "Shukra Pharmaceuticals Ltd is Rated Hold",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/shukra-pharmaceuticals-ltd-is-rated-hold-3879255",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/ShukraPharmaceu_mojoScore_3879255.png",
        "date": "2026-03-08 10:10:03",
        "description": "Shukra Pharmaceuticals Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 17 Jul 2025. However, the analysis and financial metrics discussed here reflect the company’s current position as of 09 March 2026, providing investors with an up-to-date view of its fundamentals, returns, and market standing."
      },
      {
        "title": "Shukra Pharmaceuticals Ltd is Rated Hold",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/shukra-pharmaceuticals-ltd-is-rated-hold-3855322",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/ShukraPharmaceu_mojoScore_3855322.png",
        "date": "2026-02-25 10:10:04",
        "description": "Shukra Pharmaceuticals Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 17 July 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 25 February 2026, providing investors with an up-to-date view of the company’s performance and outlook."
      },
      {
        "title": "Shukra Pharmaceuticals Ltd is Rated Hold",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/shukra-pharmaceuticals-ltd-is-rated-hold-3837234",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/ShukraPharmaceu_mojoScore_3837234.png",
        "date": "2026-02-13 10:10:05",
        "description": "Shukra Pharmaceuticals Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 17 July 2025. However, the analysis and financial metrics discussed here reflect the company’s current position as of 13 February 2026, providing investors with an up-to-date view of its fundamentals, returns, and market standing."
      },
      {
        "title": "Are Shukra Pharmaceuticals Ltd latest results good or bad?",
        "link": "https://www.marketsmojo.com/news/result-analysis/are-shukra-pharmaceuticals-ltd-latest-results-good-or-bad-3822883",
        "imagepath": "",
        "date": "2026-02-05 19:24:26",
        "description": "Shukra Pharmaceuticals Ltd has reported significant financial results for the quarter ending December 2025, marking a notable turnaround from previous periods. The company achieved a net profit of ₹20.36 crores, reflecting a substantial increase of 755.46% compared to the previous quarter. Additionally, revenue surged to ₹39.13 crores, representing a remarkable growth of 565.48% quarter-on-quarter. This performance is underscored by an operating margin of 69.33%, which is the highest recorded in the company's history, and a PAT margin of 52.03%, indicating strong profitability metrics.\n\nThe latest results suggest a significant inflection point for Shukra Pharmaceuticals, which has faced challenges in maintaining consistent performance in prior quarters. The dramatic recovery in both revenue and profit is attributed to improved product realization and effective cost management, although the company has not d..."
      }
    ],
    "total": 621,
    "sid": "505931",
    "stock_news_url": "https://www.marketsmojo.com/news/shukra-pharmaceuticals-505931"
  },
  "announcements": [
    {
      "caption": "Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018",
      "datetime": "08-Apr-2026",
      "details": "Certificate under Reg 74(5)",
      "source": "BSE"
    },
    {
      "caption": "Closure of Trading Window",
      "datetime": "20-Mar-2026",
      "details": "Closure of Trading Window",
      "source": "BSE"
    },
    {
      "caption": "Board Meeting Outcome for Independent Directors Meeting",
      "datetime": "16-Mar-2026",
      "details": "Independent Directors Meeting",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Shukra Pharmaceuticals Ltd has declared <strong>1%</strong> dividend, ex-date: 18 Sep 25",
          "dt": "2025-09-18",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "",
      "data": [
        {
          "txt": "Shukra Pharmaceuticals Ltd has announced <strong>1:10</strong> stock split, ex-date: 21 Mar 25",
          "dt": "2025-03-21",
          "middle_text": "Split"
        }
      ]
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "",
      "data": [
        {
          "txt": "Shukra Pharmaceuticals Ltd has announced <strong>3:1</strong> bonus issue, ex-date: 19 Apr 24",
          "dt": "2024-04-19",
          "middle_text": "Bonus Alert"
        }
      ]
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "",
      "data": [
        {
          "txt": "Shukra Pharmaceuticals Ltd has announced <strong>6:1</strong> rights issue, ex-date: 02 Feb 23",
          "dt": "2023-02-02",
          "middle_text": "Rights Issue"
        }
      ]
    }
  ]
}

News and Views

Shukra Pharmaceuticals Ltd is Rated Hold

2026-04-11 10:10:02

Shukra Pharmaceuticals Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 17 Jul 2025. However, the analysis and financial metrics discussed here reflect the company’s current position as of 11 April 2026, providing investors with an up-to-date view of its fundamentals, returns, and market standing.

Read full news article

Shukra Pharmaceuticals Ltd Technical Momentum Shifts Amid Mixed Indicator Signals

2026-04-07 08:02:23

Shukra Pharmaceuticals Ltd has experienced a notable shift in price momentum, reflected in a complex interplay of technical indicators that suggest a transition from a mildly bullish trend to a sideways movement. Despite a strong one-week return outperforming the Sensex, the stock’s medium-term outlook remains cautious amid mixed signals from MACD, RSI, and moving averages.

Read full news article

Shukra Pharmaceuticals Ltd is Rated Hold

2026-03-31 10:10:02

Shukra Pharmaceuticals Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 17 July 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 31 March 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Read full news article

Shukra Pharmaceuticals Ltd is Rated Hold

2026-03-20 10:10:03

Shukra Pharmaceuticals Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 17 July 2025. However, the analysis and financial metrics discussed below reflect the stock's current position as of 20 March 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.

Read full news article

Shukra Pharmaceuticals Ltd is Rated Hold

2026-03-09 10:10:02

Shukra Pharmaceuticals Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 17 Jul 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 09 March 2026, providing investors with an up-to-date perspective on the company’s performance and outlook.

Read full news article

Shukra Pharmaceuticals Ltd is Rated Hold

2026-03-08 10:10:03

Shukra Pharmaceuticals Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 17 Jul 2025. However, the analysis and financial metrics discussed here reflect the company’s current position as of 09 March 2026, providing investors with an up-to-date view of its fundamentals, returns, and market standing.

Read full news article

Shukra Pharmaceuticals Ltd is Rated Hold

2026-02-25 10:10:04

Shukra Pharmaceuticals Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 17 July 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 25 February 2026, providing investors with an up-to-date view of the company’s performance and outlook.

Read full news article

Shukra Pharmaceuticals Ltd is Rated Hold

2026-02-13 10:10:05

Shukra Pharmaceuticals Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 17 July 2025. However, the analysis and financial metrics discussed here reflect the company’s current position as of 13 February 2026, providing investors with an up-to-date view of its fundamentals, returns, and market standing.

Read full news article

Are Shukra Pharmaceuticals Ltd latest results good or bad?

2026-02-05 19:24:26

Shukra Pharmaceuticals Ltd has reported significant financial results for the quarter ending December 2025, marking a notable turnaround from previous periods. The company achieved a net profit of ₹20.36 crores, reflecting a substantial increase of 755.46% compared to the previous quarter. Additionally, revenue surged to ₹39.13 crores, representing a remarkable growth of 565.48% quarter-on-quarter. This performance is underscored by an operating margin of 69.33%, which is the highest recorded in the company's history, and a PAT margin of 52.03%, indicating strong profitability metrics. The latest results suggest a significant inflection point for Shukra Pharmaceuticals, which has faced challenges in maintaining consistent performance in prior quarters. The dramatic recovery in both revenue and profit is attributed to improved product realization and effective cost management, although the company has not d...

Read full news article

View All News